Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes

International Journal of Clinical Practice

Volumn 65, Issue 2, 2011, Pages 154-164

  Yoon, K H ^a   Shockey, G R ^b   Teng, R ^c   Golm, G T ^c   Thakkar, P R ^c   Meehan, A G ^c   Williams Herman, D E ^c   Kaufman, K D ^c   Amatruda, J M ^c   Steinberg, H ^c  

^a The Catholic University of Korea   (South Korea)

^b Clinical Research Advantage Inc   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PIOGLITAZONE; PLACEBO; SITAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ANKLE EDEMA; ARTICLE; CELL FUNCTION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOT EDEMA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; UNCONSCIOUSNESS; VOMITING;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PYRAZINES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIAZOLES;

EID: 78751562877     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02589.x     Document Type: Article

References (52)

1. Liebl A, Mata M, Eschwege E,. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45: S23-8.
2. Saydah SH, Fradkin J, Cowie CC,. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
3. Phillips LS, Twombly JG,. It's time to overcome clinical inertia. Ann Intern Med 2008; 148: 783-5.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW,. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
6. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
7. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S,. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 175-85.
8. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A,. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006; 8: 650-60.
9. Goldstein BJ, Feinglos MN, Lunceford J, Johnson J, Williams-Herman D, for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-87.
10. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003; 27 (Suppl. 2): S1-152.
11. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
12. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-51.
13. Drucker DJ, Nauck MA,. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 2006; 368: 1696-705.
14. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-9.
15. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE,. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-7.
16. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-71.
17. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care 2006; 29: 2638-43.
18. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-50.
19. Scott R, Loeys T, Davies MJ, Engel SS,. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 959-69.
20. Nauck MA, Meininger G, Sheng D, Fanurik D, Stein PP,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
21. Rosenstock J, Brazg R, Andryuk P, Lu K, Stein P,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-Blind, placebo-controlled parallel group study. Clin Ther 2006; 28: 1556-68.
22. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-83.
23. Xu L, Dalla Man C, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008; 10: 1212-20.
24. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-hour glycemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186-93.
25. Drucker DJ,. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117: 24-32.
26. Smith U,. Pioglitazone: mechanism of action. Int J Clin Pract 2001; (Suppl.): 13-8. (Pubitemid 32916691)
27. Diani AR, Sawada G, Wyse B, Murray FT, Khan M,. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 286: E116-22.
28. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA,. Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β. J Clin Endocrinol Metab 2004; 89: 5059-66.
29. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K,. Structural and functional analysis of pancreatic islet cells preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 2005; 288: E510-8.
30. Wallace TM, Levy JC, Matthews DR,. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in placebo-controlled randomized study. Diabetic Med 2004; 21: 568-76.
31. Gastaldelli A, Casoloro A, Pettiti M, et al. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther 2007; 81: 205-12.
32. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA,. Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007; 292: E871-83.
33. Cooper MB, Majali KA, bailey CJ, Betteridge DJ,. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. Clin Endocrinol 2008; 68: 738-46.
34. Aronoff S, Rosenblatt S, Braithwaite S, et al., for the Pioglitazone 001 Study Group Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-11.
35. Scherbaum WA, Göke B,. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-95.
36. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE,. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-23.
37. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL,. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22: 1395-409.
38. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL,. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-7.
39. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S,. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-7.
40. Yki-Jarvinen H,. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
41. DeFronzo RA,. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88: 787-835.
42. Bergman RN, Finegood DT, Kahn SE,. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32 (Suppl. 3): 35-45.
43. Kahn SE,. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-58.
44. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
45. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K,. Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab 2003; 285: E155-62.
46. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
47. Dungan KM, Buse JB, Largay J, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29: 1214-9.
48. Won JC, Park CY, Park HS, et al. 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res Clin Pract 2009; 84: 51-7.
49. Hodges JL, Lehmann EL,. The efficiency of some nonparametric competitors of the t-test. Ann Math Statist 1956; 27: 324-35.
50. Newcombe RG,. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-90.
51. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE,. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29: 2137-9.
52. Makimattila S, Nikkila K, Yki-Jarvinen H,. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetalogia 1999; 42: 406-12. (Pubitemid 29148398)